Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Clinical Practices Oversight Will Move To Risk-Based Approach

Executive Summary

FDA will develop a risk-based system for overseeing clinical practices, Director of Good Clinical Practice Programs David Lepay, MD/PhD, said

You may also be interested in...



Centralized IRB System Could Speed Product Development, Merck Tells CBER

A centralized institutional review board process could speed product development and reduce unnecessary paperwork, Merck regulatory affairs official Mark Bagarazzi said

Centralized IRB System Could Speed Product Development, Merck Tells CBER

A centralized institutional review board process could speed product development and reduce unnecessary paperwork, Merck regulatory affairs official Mark Bagarazzi said

FDA Foreign Trials Proposed Rule Drops Reliance On Helsinki Declaration

FDA is proposing to revise its requirements for accepting data from foreign trials not conducted under an IND

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel